ClinicalTrials.gg
RecruitingNCT05722561Updated Nov 9, 2026

E-Cigarettes for Harm Reduction in Smokers With Opioid Use Disorder

A Phase 2 interventional study of Telehealth Motivational Counseling and Nicotine Replacement Product in Opioid Use Disorder and Cigarette Smoking, sponsored by NYU Langone Health. Recruiting at 2 sites in United States. Open to participants aged 21 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-11-09.

Sponsored by NYU Langone Health · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Aug 2024; still recruiting 2 years 3 months later.
Updated Nov 9, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
302
Allocation
Randomized
Ages
21 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 23 studies in Opioid-Related Disorders by NYU Langone Health — 4 open to participants now, 5 under way, 1 of them phase 3. Opioid-Related Disorders · NYU Langone Health.

Planned enrollment
7th of 19
302 · median 217
Started
2024
the only one that year
Phase 2
3 of 23
2 open now
Registered
21st of 23
by date

Among the 23 studies in Opioid-Related Disorders by NYU Langone Health, this one is the 7th largest by planned enrollment of the 19 interventional ones that give a count, is the only one that started in 2024, is one of 3 in phase 2, and was the 21st registered.

Opioid-Related Disorders

1,476 studies on the registry are indexed under Opioid-Related Disorders; 293 are open to participants now.

Browse Opioid-Related Disorders studies →

Open to participants now

4 of the 23 studies in Opioid-Related Disorders by NYU Langone Health are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

Who these studies take

Of the 213 Opioid-Related Disorders studies recruiting now, 123 (58%) set no upper age limit and 76 (36%) stop at 75 or younger; 14 take children under 18; 53 take healthy volunteers.

This study: 21 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies in Opioid-Related Disorders by NYU Langone Health, or all of them as a file.
02

Study summary

The purpose of this an open-label, randomized controlled trial study is to compare the effectiveness of electronic cigarettes (e-cigarettes/e-cigs) versus telehealth motivational counseling with combination nicotine replacement therapy (NRT) + telehealth counseling on combustible cigarettes smoking reduction among persons with opioid use disorder (OUD) in methadone and buprenorphine treatment programs (opioid use disorder treatment programs (OUDTP)). OUDTP patients are a population with exceptionally high combustible cigarettes smoking burden and yet limited success in achieving meaningful clinical outcomes in tobacco treatment. If effective, electronic cigarettes would provide an additional tool for tobacco harm reduction among this difficult-to-treat vulnerable population.

03

Conditions studied

  • Opioid Use Disorder
  • Cigarette Smoking

Keywords

  • cigarettes
  • smoking
  • smoking reduction
  • OUD
  • OUDTP
  • Buprenorphine
  • Methadone
04

Who can participate

Ages eligible
21 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Currently smokes 5 or more CPD
  2. Age ≥ 21 years
  3. Has a diagnosis of Opioid Use Disorder
  4. In OUDTP (buprenorphine or methadone) ≥ 12 weeks via self-report or EHR records
  5. Stable methadone or buprenorphine dose for two weeks via self-report or EHR records
  6. Interested in reducing combustible cigarette (CC) smoking but not necessarily trying to quit
  7. Own a mobile phone or have regular access to a mobile phone.
  8. Able to provide an additional contact to improve follow-up rates.

Exclusion criteria

Exclusion Criteria:

  1. Does not speak English or Spanish
  2. Are pregnant or breastfeeding
  3. Not able to provide consent
  4. Used tobacco products other than CC in the past 2 weeks (e.g., EC, cigarillo)
  5. Currently engaged in an attempt to quit CC smoking
  6. Reports having severe or asthma (i.e., with exacerbation requiring hospitalization or intubation in the prior 6 months)
  7. Reports current major depressive or manic episode, current psychotic disorder, past-year suicide attempt or psychiatric hospitalization, or current suicidal ideation with plan or intent.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
302 participants (estimated)

Study arms

  • Experimental
    Electronic Cigarette

    Participants in the Electronic Cigarette (EC) arm will receive telehealth motivational counseling for 5 weeks plus the standardized research e-cigarette (SREC).

    Behavioral: Telehealth Motivational Counseling · Device: National Institute on Drug Abuse (NIDA) Standardized Research Electronic Cigarette (SREC).

  • Active comparator
    Nicotine Replacement Therapy

    Participants in the Nicotine Replacement Therapy (NRT) arm will receive telehealth motivational counseling plus combination NRT (patch and lozenge).

    Behavioral: Telehealth Motivational Counseling · Drug: Nicotine Replacement Product

Interventions

  • BehavioralTelehealth Motivational Counseling

    At baseline, after randomization, participants will receive their first telehealth session (20\~25 minutes) from a counselor trained in motivational interviewing, harm reduction, and smoking cessation. Four additional sessions will be delivered (weeks 2, 3, 4, 6), 15\~20 minutes each.

  • DrugNicotine Replacement Product

    Combination nicotine replacement therapy with lozenges and patches. Participants are recommended to use the NRT according to product directions.

  • DeviceNational Institute on Drug Abuse (NIDA) Standardized Research Electronic Cigarette (SREC).

    Participants are to use the electronic cigarette freely as replacement for smoking combustible cigarettes.

06

What researchers measure

Primary outcomes

  1. Percentage of Participants who Achieve 100% Reduction in Cigarettes Per Day (CPD) between Baseline and End of Intervention (Visit 5)

    Verified by exhaled carbon-monoxide (eCO) level.

    Time frame: Up to Visit 5 (Day 56)

Secondary outcomes

  1. Percentage of Participants who Achieve 100% Reduction in CPD between Baseline and Month 6 Follow-Up

    Verified by exhaled carbon-monoxide (eCO) level.

    Time frame: Month 6

  2. Percentage of Participants who Achieve 100% Reduction in CPD between End of Intervention (Visit 5) and Month 6 Follow-Up

    Verified by exhaled carbon-monoxide (eCO) level.

    Time frame: From Visit 5 (Day 56) up to Month 6

  3. Change from Baseline in Self-Reported CPD at End of Intervention (Visit 5)

    Verified by exhaled carbon-monoxide (eCO) level.

    Time frame: Baseline, Visit 5 (Day 56)

  4. Change from Baseline in Self-Reported CPD at Month 6

    Verified by exhaled carbon-monoxide (eCO) level.

    Time frame: Baseline, Month 6

  5. Change from Baseline in Health-Related Quality of Life (HRQOL) Survey Score at End of Intervention (Visit 5)

    8-item self assessment of participants' perceived physical and mental health over time. Each item lists a condition. For each item, participants indicate the number of days the condition applied to them. The total score is the average of responses and ranges from 0-30. Lower scores indicate greater perceived physical and mental health. A reduction in scores indicates perceived physical and mental health improved over the observational period.

    Time frame: Baseline, Visit 5 (Day 56)

  6. Change from Baseline in Health-Related Quality of Life (HRQOL) Survey Score at Month 6 Follow-up

    8-item self assessment of participants' perceived physical and mental health over time. Each item lists a condition. For each item, participants indicate the number of days the condition applied to them. The total score is the average of responses and ranges from 0-30. Lower scores indicate greater perceived physical and mental health. A reduction in scores indicates perceived physical and mental health improved over the observational period.

    Time frame: Baseline, Month 6

  7. Number of Respiratory Symptoms Reported at Baseline

    Time frame: Baseline

  8. Number of Respiratory Symptoms Reported at End of Treatment (Visit 5)

    Time frame: Visit 5 (Day 56)

  9. Number of Respiratory Symptoms Reported at Month 6 Follow-up

    Time frame: Month 6

07

Study locations

1 of 2 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — The de-identified participant data from the final research dataset used in the published manuscript will be shared upon reasonable request beginning 9 months and ending 36 months following article publication or as required by a condition of awards and agreements supporting the research provided the investigator who proposes to use the data executes a data use agreement with NYU Langone Health. Requests may be directed to: [Omar.ElShahawy@nyulangone.org]. The protocol and statistical analysis plan will be made available on Clinicaltrials.gov only as required by federal regulation or as a condition of awards and agreements supporting the research.

Supporting information: Study protocol, Statistical analysis plan

Time frame: Beginning 9 months and ending 36 months following article publication or as required by a condition of awards and agreements supporting the research.

Access criteria: The investigator who proposed to use the data and researchers who provide a methodologically sound proposal will be granted access to the data upon reasonable request. Requests should be directed to Omar.ElShahawy@nyulangone.org. To gain access, data requestors will need to sign a data access agreement.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2024 (actual). Primary completion is estimated for Feb 2027, 30 months after the start.

Of 61 non-industry phase 2 interventional studies under Opioid-Related Disorders, half reached primary completion within 41 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 55. This study's planned 30 months is below that.

Counting every sponsor, half of 68 studies reached it within 40 months; a quarter within 23 and three quarters within 55.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 9, 2026: primary completion Nov 2026 → Feb 2027 and completion Mar 2027 → Apr 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Feb 1, 2023
First posted
Feb 10, 2023
StartActual
Aug 8, 2024
Primary completionEst.
Feb 10, 2027was Nov 2026
CompletionEst.
Apr 30, 2027was Mar 2027
Last update
Nov 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Nov 1, 2026→Feb 10, 2027
Nov 9, 2026
Study completion
Mar 1, 2027→Apr 30, 2027
Nov 9, 2026
Show all 1 update
  1. Nov 9, 2026
    Primary completion Nov 1, 2026→Feb 10, 2027
    Study completion Mar 1, 2027→Apr 30, 2027
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05722561
Lead sponsor
NYU Langone Health
Responsible party
Sponsor
First posted
Feb 10, 2023
Start date
Aug 8, 2024
Primary completion
Feb 10, 2027 (estimated)
Completion
Apr 30, 2027 (estimated)
Last update
Nov 9, 2026

Study contacts

Omar El-Shahawy, MD, MPH, PhD
Contact
Omar.ElShahawy@nyulangone.org
646-501-3587
Mohsen Abbasi, MD, MPH
Contact
Mohsen.Abbasikangevari@nyulangone.org
646-501-3581
Omar El-Shahawy
principal investigator · NYU Langone Health

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion